Behavioral Health Pharmacy Altruix Approved To Dispense Brixadi® LAI For Moderate-To-Severe Opioid Use Disorder

Altruix, which provides behavioral health pharmacy solutions in 23 states, has been selected as a limited distribution partner by Braeburn Inc. for Brixadi, a long-acting injection (LAI) of buprenorphine used to for maintenance treatment of moderate-to-severe opioid use disorder. Altruix consists of the combined operations of the former Terrapin Pharmacy, Bank’s Apothecary, and Altruix in Lancaster (formerly Ganse Apothecary).

Brixadi is an extended-release injection approved by the U.S. Food and Drug Administration (FDA) to treat moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal . . .